Jade Biosciences, Inc. (JBIO) Form 424B5 — Jun 3, 2026
Jade Biosciences, Inc. (JBIO) filed a preliminary prospectus supplement for an equity offering of common stock and pre-funded warrants, utilizing its existing $600 million shelf registration. The offering is timed with the announcement of positive Phase 1 interim results for its lead candidate JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, which demonstrated approximately 70% IgA reduction and a favorable safety profile in healthy volunteers. The filing discloses that Jade had 49.3 million shares outstanding as of March 31, 2026, with a net tangible book value of $296.5 million ($6.00 per share).
Key figures
- Closing Price
- 17.75
- Shares Outstanding
- 49345967
- Net Tangible Book Value
- 296500000
- Net Tangible Book Value Per Share
- 6
- Atm Capacity
- 200000000
- Shelf Capacity
- 600000000
- Jade101 Ig AReduction
- 70%
- Jade101 Half Life Vs Povetacicept
- 8.7x
- Jade101 Potency Vs Sibeprenlimab
- 379x
Price after filing
Close on the filing date to close N calendar days later (from $17.59). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.